Named on 2 rounds in the feed, most often in Biotech.
Rounds from 2026-11-17 to 2026-11-17
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Marrow Therapeutics An experimental treatment for sickle cell disease and beta thalassemia that aims to deliver genetic medicines directly to bone marrow cells. | Series B contradicted | $120M | 2026-11-17 | [ PART ] |
Marrow Therapeutics An experimental treatment for sickle cell disease and beta thalassemia that aims to deliver genetic medicines directly to bone marrow cells. | Series A Verified against 4 of 15 sources | $173M | 2026-11-17 | [ PART ] |